References
- 1. Grönberg H. Prostate cancer epidemiology. Lancet Lond Engl. 2003;361(9360):859–864.10.1016/S0140-6736(03)12713-4
- 2. Globocan 2012. Available from: http://globocan.iarc.fr/Default.aspx
- 3. Benoit RM, Naslund MJ. The socioeconomic implications of prostate-specific antigen screening. Urol Clin North Am. 1997;24(2):451–458.10.1016/S0094-0143(05)70392-X
- 4. Krpina K, Markić D, Rahelić D, Ahel J, Rubinić N, Španjol J. 10-year survival of a patient with metastatic prostate cancer: Case report and literature review. Arch Ital Urol Androl. 2015;87(3):252-3. doi: 10.4081/aiua.2015.3.252.10.4081/aiua.2015.3.25226428652
- 5. Slipman CW, Patel RK, Siegelman ES, et al. Metastatic prostate cancer to the spine and a PSA of 5666: a case report. Pain Physician. 2001;4(4):317–321.10.36076/ppj.2001/4/317
- 6. Persec Z, Persec J, Sović T, Romic Z, Bosnar Herak M, Hrgovic Z. Metastatic prostate cancer in an asymptomatic patient with an initial prostate-specific antigen (PSA) serum concentration of 21,380 ng/ml. Onkologie. 2010;33(3):110–112. doi: 10.1159/000277743.10.1159/00027774320215802
- 7. Dantanarayana ND, Hossack T, Cozzi P, et al. Men under the age of 55 years with screen detected prostate cancer do not have less significant disease compared to older men in a population of patients in Australia. BMC Urol. 2015;15(1):124. doi: 10.1186/s12894-015-0117-3.10.1186/s12894-015-0117-3469623326715039
- 8. Andriole GL, Crawford ED, Grubb RL, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104(2):125–132. doi: 10.1093/jnci/djr500.10.1093/jnci/djr500326013222228146
- 9. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320–1328. doi: 10.1056/NEJMoa081008410.1056/NEJMoa081008419297566
- 10. Buzzoni C, Auvinen A, Roobol MJ, et al. Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer. Eur Urol. 2015;68(5):885–890. doi: 10.1016/j.eururo.2015.02.042.10.1016/j.eururo.2015.02.042498286925791513
- 11. Schröder FH, Hugosson J, Carlsson S, et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol. 2012;62(5):745–752. doi: 10.1016/j.eururo.2012.05.068.10.1016/j.eururo.2012.05.06822704366
- 12. Woolf SH. Public health perspective: the health policy implications of screening for prostate cancer. J Urol. 1994;152(5 Pt 2):1685–1688.10.1016/S0022-5347(17)32361-3
- 13. Sun M, Choueiri TK, Hamnvik O-PR, et al. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy. JAMA Oncol. 2016;2(4):500-507. doi: 10.1001/jamaoncol.2015.4917.10.1001/jamaoncol.2015.491726720632
- 14. Nyman CR, Andersen JT, Lodding P, Sandin T, Varenhorst E. The patient’s choice of androgen-deprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin-releasing hormone analogue or orchidectomy. BJU Int. 2005;96(7):1014–1018.10.1111/j.1464-410X.2005.05802.x16225519
- 15. Leidinger P, Hart M, Backes C, et al. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status. Tumour Biol. 2016;37(8):10177-10185. doi: 10.1007/s13277-016-4883-7.10.1007/s13277-016-4883-726831660